Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$163.58M-45.11%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Phillip Frost
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 2,275
- Beta
- 1.50
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.24
Financials
Revenue
$163.58M-45.1%Net Income
$-8.42MEBITDA
$12.00MFree Cash Flow
$-46.50MEPS (diluted)
$-0.01Shares Outstanding (diluted)
755.27M+51.1%Operating Expenses
$86.09MCash & Debt
$300.76MReturn of Capital
$13.02MRevenue by Segment (annual)
$606.88MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $606.88M | $-225.68M | $-0.30 |
| 2024 | $713.14M | $-53.22M | $-0.08 |
| 2023 | $863.50M | $-188.86M | $-0.25 |
| 2022 | $1.00B | $-328.40M | $-0.46 |
| 2021 | $1.77B | $-30.14M | $-0.05 |
| 2020 | $1.44B | $30.59M | $0.05 |
| 2019 | $901.93M | $-314.93M | $-0.53 |
| 2018 | $990.30M | $-153.04M | $-0.27 |
| 2017 | $966.01M | $-305.25M | $-0.55 |
| 2016 | $1.22B | $-48.36M | $-0.05 |
| 2015 | $491.70M | $-30.03M | $-0.06 |
| 2014 | $91.10M | $-171.67M | $-0.41 |
| 2013 | $96.53M | $-114.41M | $-0.32 |
| 2012 | $47.04M | $-29.05M | $-0.11 |
Valuation
OPKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+11.11%Social Signal Score
Mentions (11)
- Newszacks.com·7d ago·Neutral
Here's Why You Should Retain OPK Stock in Your Portfolio for Now OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
View source ↗ - Newszacks.com·14d ago·Positive
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026? OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.
View source ↗ - Newsmarketbeat.com·25d ago·Neutral
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.
View source ↗ - Newszacks.com·40d ago·Neutral
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report? OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·42d ago·Neutral
Here's Why You Should Retain OPK Stock in Your Portfolio for Now OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
View source ↗ - Newszacks.com·47d ago·Neutral
OPK Raises $125 Million Against Royalties: What Investors Should Know OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
View source ↗ - Newszacks.com·47d ago·Neutral
Is OPK Worth Buying as Valuation Meets Improving Business Trends? OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
View source ↗ - Newszacks.com·47d ago·Neutral
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going? OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.
View source ↗ - Newszacks.com·48d ago·Positive
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.07 per share
Typical surprise +42.9% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Jul 27$-0.01 vs $-0.08beat
- Tue, Apr 28$-0.07 vs $-0.07beat
- Thu, Feb 26$-0.04 vs $-0.07beat
- Wed, Oct 29$0.03 vs $-0.02beat
- Thu, Jul 31$-0.19 vs $-0.12miss
- Wed, Apr 30$-0.10 vs $-0.06miss
Estimates and results for OPK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OPK officers and directors.
- Bought
- $10.1m
- Sold
- —
56 trades
0 trades
- Paganelli John Abought
- Frost Phillip Md Et Albought
- Frost Phillip Md Et Albought
- Frost Phillip Md Et Albought
- Frost Phillip Md Et Albought
- Frost Phillip Md Et Albought
- Frost Phillip Md Et Albought
- Frost Phillip Md Et Albought
39 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OPK.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.